Clinical Trials
Sep 23, 2026 · 1 min read · 85,555 views
Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease
M
Maya Chen
Editorial · Sep 23, 2026
Investors are pumping $123 million into a tiny Michigan biotech that is resurrecting linsitinib for an eye disease that has attracted lots of VC and pharma attention in recent years
← Previous
Telix and radioisotope maker ITM merge in deal worth up to $2.35B
Next →
Roivant's road to a potential blockbuster begins with FDA approval for Lisraya
